Addimmune™

Addimmune is changing the way we treat HIV. With our unique gene therapy approach, we believe HIV will no longer be a life-long sentence, but a curable illness.

[Addimmune™ @Addimmune]

AGT has completed two clinical trials for our HIV CURE PROJECT with promising data. Now we need your help to try to take it to the finish line. Please consider donating today or sharing with someone who could.
https://t.co/w9U1XVLvI8
#HIVCure #HIV #Donate

[Addimmune™ @Addimmune]

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment.
https://t.co/7CTxzCqsi6
#HIV #celltherapy #biotech

[Addimmune™ @Addimmune]

AGT CEO, Jeff Galvin, had a chat with HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Discover what lies ahead in our mission to find a cure for HIV!
https://t.co/ZNvqbK9woO
#HIVResearch #ClinicalTrials

[Addimmune™ @Addimmune]

Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. https://t.co/npUKqr4vAj
#genetics #science #healthcare

[Addimmune™ @Addimmune]

Dr. Marcus Conant will be participating in a roundtable on cell and #GeneTherapy alongside Andrew Dietz, MD, of @ShapeTX at this year’s CMO Summit 360 on April 18 at 12:50 PM ET. Learn more: https://t.co/SnNOgwVDjj #CMO360

[Addimmune™ @Addimmune]

Dr. Marcus Conant will be participating in a roundtable on cell and #GeneTherapy alongside Andrew Dietz, MD, of @ShapeTX at this year’s CMO Summit 360 on April 18 at 12:50 PM ET. Learn more: https://t.co/25BRxAq70W #CMO360

[Addimmune™ @Addimmune]

The future of medicine! The strategic market insight company Nova 1 values the cell & gene therapy market @ $18 billion in 2023 growing at a CAGR of 18% over the next decade. They see a near $100 billion market size by 2033.
https://t.co/h5ZGPBlOko
#genetherapy #futureofmedicine

[Addimmune™ @Addimmune]

This #NYHAAD, we support @NYHAAD and their mission to create meaningful and intentional spaces for young people to ask questions, learn, and talk about the impacts of HIV and their community. #StopHIVTogether #EndHIVStigma

[Addimmune™ @Addimmune]

This #NYHAAD, we support @NYHAAD and their mission to create meaningful and intentional spaces for young people to ask questions, learn, and talk about the impacts of HIV and their community. #StopHIVTogether #EndHIVStigma

[Addimmune™ @Addimmune]

Listen in with Dr. Marcus Conant as he discusses #genetherapy for HIV suppression with CGTLive here https://t.co/qBxbFp2kXm

[Addimmune™ @Addimmune]

Recent article highlights 6 recent cell & gene therapies & looks ahead to 17 more mentioned by the Alliance for Regenerative Medicine. Many have been able to leverage abbreviated pathways.
https://t.co/ad5WE0qBdn

[Addimmune™ @Addimmune]

We are grateful to have Dr. Marcus Conant represent our mission to find a functional cure for #HIV, especially at #CROI2024. Learn about his journey in @PharmaVoice: https://t.co/X9NQq1O1uJ

[Addimmune™ @Addimmune]

More signs of continued momentum in the biotech industry!
Green shoots in IPO land with @boundlessbio following last month's @Kyverna_Tx & @altoneuro's debut on the exchanges. ecDNA oncology company will launch $100 million IPO.
https://t.co/2TdxI0404m
$BOLD $KYTX $ANRO

[Addimmune™ @Addimmune]

🚨 TONIGHT! - Mar 27th, 4PM EST🚨 Catch AGT's CEO, Jeff Galvin, on DC News Now's "Moco Minute." He'll discuss HIV research from AGT and its HIV division, Addimmune, the future of the biotech industry and pushing innovation. https://t.co/7dJOudl0Z0
#AGT #Addimmune #MocoMinute

[Addimmune™ @Addimmune]

#ICYMI, our Chief Science Officer, Jeff Boyle, PhD, was featured in the 2024 March issue of @PharmTechGroup providing commentary and insight on the development of Gamma-Delta T-cell therapies – and how we are leveraging #GeneTherapy. Read more: https://t.co/iCoJMGGOjm

[Addimmune™ @Addimmune]

On this National Native HIV and AIDS Awareness Day (#NNHAAD), we're rallying behind a national movement to empower Native communities across the US and its territories to learn about the disease, get tested, join prevention efforts, and seek care for #HIV.

[Addimmune™ @Addimmune]

@Mustang_Bio achieves CAR-T success with recurrent brain cancer. 70% improvement in survival as reported in Nature, The science is advancing! Fierce Biotech article: https://t.co/gIFBVSnzRQ
#science #biotech #success
RT to help spread awareness of this amazing CAR-T progress!

[Addimmune™ @Addimmune]

Public biotechs have raked in $10 billion this year, and the XBI is up over 50%! Gene therapy leaders are driving the momentum. https://t.co/ie76vLFQSI
#FOMO #biotech #investing
Are you seeing this trend too? Let us know with a 👍

[Addimmune™ @Addimmune]

Today is National Women and Girls HIV/AIDS Awareness Day. The National HIV/AIDS Strategy provides a national strategy to accelerate efforts to end the #HIV epidemic by 2030. Click here to read a summary: https://t.co/nUK9pPCiZq #NWGHAAD

[Addimmune™ @Addimmune]

Our team is attending the 31st Conference on Retroviruses and Opportunistic Infections presented by @IAS_USA! We are eager to engage with our peers in the HIV research community & share the progress we're making towards finding a functional cure for HIV. https://t.co/RWX3w1YkAC